Nu-Med Plus (NUMD) Cash from Operations Growth (3y) (2015 - 2025)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | 4.78% |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 9.30% |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | 20.35% |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 22.35% |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | -48.14% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 0.50% |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 50.11% |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | -14.75% |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 15.83% |
| 10 | Nu-Med Plus | - | - | - | -12.79% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -12.79% |
| Sep 30, 2025 | -172.24% |
| Dec 31, 2024 | 56.43% |
| Jun 30, 2024 | 67.34% |
| Mar 31, 2024 | 82.16% |
| Dec 31, 2023 | 60.83% |
| Sep 30, 2023 | 42.84% |
| Jun 30, 2023 | 46.10% |
| Mar 31, 2023 | 40.39% |
| Dec 31, 2022 | 41.91% |
| Sep 30, 2022 | 26.17% |
| Jun 30, 2022 | 72.39% |
| Mar 31, 2022 | 63.36% |
| Dec 31, 2021 | 47.99% |
| Sep 30, 2021 | 34.05% |
| Jun 30, 2021 | 12.61% |
| Mar 31, 2021 | 1.04% |
| Dec 31, 2020 | 20.00% |
| Sep 30, 2020 | 7.55% |
| Jun 30, 2020 | -18.03% |
| Mar 31, 2020 | -8.80% |
| Dec 31, 2019 | -44.59% |
| Sep 30, 2019 | -24.67% |
| Jun 30, 2019 | -34.25% |
| Mar 31, 2019 | -69.94% |
| Dec 31, 2018 | -44.49% |
| Sep 30, 2018 | -53.79% |
| Jun 30, 2018 | -23.54% |
| Mar 31, 2018 | -23.61% |
| Dec 31, 2017 | -55.92% |
| Sep 30, 2017 | -53.58% |
| Jun 30, 2017 | -28.35% |
| Mar 31, 2017 | -18.98% |
| Sep 30, 2016 | -0.62% |
| Jun 30, 2016 | -14.75% |
| Mar 31, 2016 | -11.65% |
| Dec 31, 2015 | 23.09% |
| Sep 30, 2015 | -13.66% |
| Jun 30, 2015 | -41.82% |
| Mar 31, 2015 | -13.61% |